The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.
Christian Kurzeder
Honoraria - Roche
Other Remuneration - Roche
Jose Maria Del Campo
No relevant relationships to disclose
Patricia Pautier
Consultant or Advisory Role - AstraZeneca; PharmaMar; Roche
Felix Hilpert
Consultant or Advisory Role - Roche
Honoraria - Roche
Angiolo Gadducci
No relevant relationships to disclose
Petronella Ottevanger
No relevant relationships to disclose
Domenica Lorusso
Consultant or Advisory Role - Roche
Research Funding - Roche
Ignace Vergote
Consultant or Advisory Role - Roche (U)
Research Funding - University of Leuven
Isabel Bover
No relevant relationships to disclose
Michel Fabbro
No relevant relationships to disclose
Frederik Marmé
Honoraria - Amgen; Celgene; Novartis; Roche
Other Remuneration - Amgen; Celgene; Novartis; Roche
Yolanda Garcia
No relevant relationships to disclose
Frédéric Selle
No relevant relationships to disclose
Martina Gropp-Meier
No relevant relationships to disclose
Beatriz Pardo
No relevant relationships to disclose
Ulrich Freudensprung
Employment or Leadership Position - Roche
Ru-Amir Walker
Employment or Leadership Position - Roche
Stock Ownership - Roche
Antonio Gonzalez-Martin
No relevant relationships to disclose